ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments: Sleep and Respiratory Care and Software as a Service. On the other hand, Vivos Therapeutics, Inc. (VVOS) is a medical technology company that develops and commercializes treatment alternatives for patients with sleep-disordered breathing, such as mild-to-moderate obstructive sleep apnea.
As the healthcare sector’s focus has been shifting on treating several diseases that lacked enough attention last year due to the COVID-19 pandemic, the sleep apnea devices industry should witness significant growth this year. While supply chain issues are still a major concern, the surging sleep apnea cases and geriatric population have been leading to solid demand. The industry should keep growing with increasing awareness of the condition, a rising need for diagnostic testing, and rapid innovation. According to a Fortune Business Insights report, the global sleep apnea devices market is expected to grow at a 7.1% CAGR by 2028. Therefore, both RMD and VVOS should benefit.
